Timing of allogeneic stem cell transplantation for myelodysplastic syndromes and aplastic anemia | Aplastic Anemia and MDS International Foundation

Timing of allogeneic stem cell transplantation for myelodysplastic syndromes and aplastic anemia

Journal Title: 
Hematology Am Soc Hematol Educ Program
Author(s): 
Cutler C
Primary Author: 
Cutler C
Original Publication Date: 
Friday, December 5, 2014

Allogeneic hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS) is a potentially curative procedure, but is associated with a significant risk of morbidity and mortality. With the recent approval of disease-modifying agents, the appropriate timing of allogeneic HSCT needs to be addressed. Similarly, the optimal use of these disease-modifying agents before HSCT needs to be determined. In severe aplastic anemia, HSCT is a proven cure, but HLA-matched sibling donors are found in fewer than 25% of newly diagnosed patients. The use of early unrelated donor HSCT is an evolving concept that will become more accepted as improvements in HSCT outcomes continue.

Bone Marrow Diseases: